Cardiff Oncology第四季度GAAP每股收益$(0.21)优于预期$(0.24),销售额$151.00K优于预期$94.17K

财报速递2025-02-28
Cardiff Oncology(纳斯达克股票代码:CRDF)报告季度每股亏损$(0.21),优于分析师一致预期的$(0.24),增长了12.5%。与去年同期持平。公司报告季度销售额为$151.00千,优于分析师一致预期的$94.17千,增长了60.35%。与去年同期的销售额$156.00千相比下降了3.21%。

以上内容来自Benzinga Earnings专栏,原文如下:

Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.24) by 12.5 percent. This is unchanged from the same period last year. The company reported quarterly sales of $151.00 thousand which beat the analyst consensus estimate of $94.17 thousand by 60.35 percent. This is a 3.21 percent decrease over sales of $156.00 thousand the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法